The CALIBRATE study of encaleret for patients with ADH1 met all pre-specified primary and key secondary efficacy endpoints - The primary endpoint was met with 76% of participants administered ...
The latest update is out from Addex Therapeutics ( (CH:ADXN) ).
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ...
Abstract: An accurate understanding of modulation-induced motor losses in inverter-fed traction drives is essential for optimizing inverter operation and designing high-efficiency motor drives.
Investing.com -- Neumora Therapeutics Inc (NASDAQ:NMRA) stock jumped 8.4% in premarket trading Monday after the company reported positive preclinical data for its obesity drug candidate and received ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical stud ...
TipRanks on MSN
Neumora Therapeutics Begins Phase 1 Study for NMRA-898
The latest announcement is out from Neumora Therapeutics, Inc. ( ($NMRA) ). On October 27, 2025, Neumora Therapeutics announced the initiation of ...
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical ...
MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...
The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...
QTX3034 monotherapy and the QTX3034-cetuximab combination demonstrated favorable safety profiles and clear clinical proof of concept, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback